WEBULL
News
KOD
24.34
-1.70%
-0.42
Kodiak Sciences: Retinal Specialist Highlights Its Top Three Programs
Seeking Alpha · 3d ago
Weekly Report: what happened at KOD last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at KOD last week (1117-1121)?
Weekly Report · 11/24 10:11
Kodiak Sciences Is Maintained at Neutral by Chardan Capital
Dow Jones · 11/17 12:24
Kodiak Sciences Price Target Maintained With a $14.00/Share by Chardan Capital
Dow Jones · 11/17 12:24
Chardan Capital Maintains Neutral on Kodiak Sciences, Maintains $14 Price Target
Benzinga · 11/17 12:14
Kodiak Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/17 12:03
Kodiak Sciences Price Target Raised to $26.00/Share From $24.00 by HC Wainwright & Co.
Dow Jones · 11/17 12:03
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $26
Benzinga · 11/17 11:53
Kodiak Sciences’ Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic Adjustments
TipRanks · 11/17 11:25
Kodiak Sciences price target raised to $26 from $24 at H.C. Wainwright
TipRanks · 11/17 11:20
KODIAK SCIENCES INC. <KOD.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $26 FROM $24
Reuters · 11/17 11:08
Weekly Report: what happened at KOD last week (1110-1114)?
Weekly Report · 11/17 10:11
Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)
TipRanks · 11/17 09:46
U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living
Reuters · 11/17 08:05
Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (SPRO), Kodiak Sciences (KOD) and VolitionRX (VNRX)
TipRanks · 11/17 06:50
Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy Rating
TipRanks · 11/14 13:55
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
NASDAQ · 11/14 12:36
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
Reuters · 11/14 09:48
KODIAK SCIENCES INC <KOD.O>: JEFFERIES RAISES TARGET PRICES TO $24 FROM $22
Reuters · 11/14 04:51
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.